A5025258309- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Advanced Radiotherapy Techniques
- Cancer Research and Treatments
- Ferroptosis and cancer prognosis
- Colorectal Cancer Treatments and Studies
- Breast Cancer Treatment Studies
- Cancer, Lipids, and Metabolism
- Glioma Diagnosis and Treatment
- Cancer Risks and Factors
- Cancer Treatment and Pharmacology
- Curcumin's Biomedical Applications
- Retinoids in leukemia and cellular processes
- Brain Metastases and Treatment
- Metabolism, Diabetes, and Cancer
- Therapeutic Uses of Natural Elements
- Complementary and Alternative Medicine Studies
- Lung Cancer Treatments and Mutations
- Circadian rhythm and melatonin
- Chemotherapy-induced cardiotoxicity and mitigation
- Health, psychology, and well-being
- Prostate Cancer Treatment and Research
- Nutrition and Health in Aging
- PARP inhibition in cancer therapy
Centre Jean Perrin
2018-2025
Inserm
2019-2025
Université Clermont Auvergne
2020-2025
Sigma Clermont
2024
Clinical Investigation Center Plurithematic Tours
2024
Imagerie Moléculaire et Stratégies Théranostiques
2018-2023
Abstract Background Metastatic castration‐resistant prostate cancer (mCRPC) patients have a poor prognosis, and curcumin is known to antineoplastic properties. On the basis of previous phase I II studies, we investigated whether association with docetaxel could improve prognosis among mCRPC patients. Methods A total 50 (included from June 2014 July 2016) treated in oral (6 g/d for 7 days every 3 weeks) versus placebo were included this double‐blind, randomized, study. The primary endpoint...
Eribulin can represent a therapeutic alternative for patients with advanced breast cancer who have received at least one or two lines of anthracyclines-based chemotherapy and taxane therapy. In this observational study, we focused on long-responder patients, i.e. an objective response stability ≥ 6 months under eribulin to better characterize them. Metastatic (MBC) treated by in 2nd, 3rd 4th line between September 2011 June-2018 were included. The following parameters assessed: primary tumor...
Abstract Background Over the past twenty years, post-cancer rehabilitation has been developed, usually in a hospital setting. Although this allows better care organization and improved security, it is perceived as stressful restrictive by “cancer survivor”. Therefore, transfer of benefits to everyday life more difficult, or even uncertain. Staying thermal resort seemed offer good compromise: security structure centralized reception for treatment medical supervision, accommodation hotel with...
Abstract Background and Aims The treatment of metastatic non‐small‐cell lung cancer (NSCLC) has been revolutionized by the arrival immune checkpoint inhibitors (ICI). For patients without related adverse events (irAEs), it is recommended to continue as long provides clinical benefit or until unacceptable toxicity appears. aim our study was evaluate survival data among with advanced NSCLC following ICI discontinuation for reasons long‐term response (irAEs). Methods We included all treated...
Abstract Background In this study, we investigated whether the association of curcumin and docetaxel among advanced metastatic breast cancer patients in first or second‐line treatment potentiated objective response rate. Patients/Methods A multicentre, randomized, open label, phase‐II study was conducted included 42 from July 2009 to January 2017. The primary endpoint rate docetaxel‐curcumin combination comparison with alone. secondary endpoints were assessment clinical benefit, overall...
Background/Aim: Triple-negative breast cancer (TNBC) is the most heterogeneous subtype, posing numerous challenges in clinical decision-making. Biomarkers are essential to personalize management of TNBC patients. While tumor infiltrating lymphocytes (TILs) validated prognostic biomarkers, requirement for biopsy limits their routine use. Therefore, more accessible and reliable quantitative biomarkers needed. Given significant role systemic inflammatory response onset progression, assessing...
<ns3:p><ns3:bold>Introduction: </ns3:bold>Patient-derived xenografts (PDX) can be used to explore tumour pathophysiology and could useful better understand therapeutic response in breast cancer. PDX from mammary tumours are usually made metastatic tumours. Thus, primitive or after neoadjuvant treatment still rare. This study aims assess the feasibility establish samples of patients with triple negative luminal B cancer neoadjuvant, adjuvant setting.</ns3:p><ns3:p> <ns3:bold>Methods:...
<ns3:p><ns3:bold>Introduction: </ns3:bold>Patient-derived xenografts (PDX) can be used to explore tumour pathophysiology and could useful better understand therapeutic response in breast cancer. PDX from mammary tumours are usually made metastatic tumours. Thus, primary or after neoadjuvant treatment still rare. This study aims assess the feasibility establish samples of patients with triple negative luminal B cancer neoadjuvant, adjuvant setting.</ns3:p><ns3:p> <ns3:bold>Methods:...
Currently, the long-term prognosis and survival rate of patients with high-grade glial tumors remains poor there are no biomarkers. hPG80 (circulating progastrin) secreted into blood by tumor cells has been widely studied in colorectal cancer. Its involvement tumorigenesis demonstrated literature. Moreover, according to a recent study, is expressed cancer at significantly higher concentration than control group composed healthy donors.The PROGLIO study pilot, single-center, longitudinal that...
Abstract Despite considerable progress in understanding the biology and genetics of breast cancer, development effective therapies needs physiological predictive preclinical models. In this context, cancer (BC) patient-derived xenograft (PDX) models have become a standard tool as they reproduce tumors origin, term histology, genotype response to chemotherapy. They proven their relevance study pathways leading progression mechanisms linked tumor resistance identification novel therapies. We...
Abstract Background: Durable responses of triple negative breast cancer (TNBC) to pembrolizumab (anti-PD-1) or atezolizumab (anti-PD-L1) have been reported in the metastatic setting. Moreover, it is currently being hypothesized that immune checkpoint inhibitors might be more effective neoadjuvant setting, due better preserved anti-tumor immunity early TN disease. However, biomarkers predictive response anti-PD-1 anti-PD-L1 agents, as well biomarker-based strategies for testing those drugs...
Abstract Background: Triple negative breast cancer (TNBC) is the most heterogeneous subtype of cancer. However, initial treatment this disease still dichotomous: 1st-line surgery (Surg1) followed by adjuvant chemotherapy, or neoadjuvant chemotherapy (NACT) surgery. After radiotherapy, patients (pts) are only observed until recurrence. Our team has pointed earlier (SABCS 2017) that some TNBCs recur very rapidly, in less than 12 months (mo) after NACT. Pts with those tumors have a poor...
<ns3:p><ns3:bold>Introduction: </ns3:bold>Patient-derived xenografts (PDX) can be used to explore tumour pathophysiology and could useful better understand therapeutic response in breast cancer. PDX from mammary tumours are usually made metastatic tumours. Thus, primary or after neoadjuvant treatment still rare. This study aims assess the feasibility establish samples of patients with triple negative luminal B cancer neoadjuvant, adjuvant setting.</ns3:p><ns3:p> <ns3:bold>Methods:...